#immunotherapy

A first-in-human phase 1 study of IMA401 found manageable side effects and early antitumor activity in advanced solid tumors.

A report highlighted ultra-low-dose immunotherapy as a possible way to widen access to expensive cancer treatment in poorer countries.

A small randomized trial suggests the anti-inflammatory drug tocilizumab may ease symptoms in people with moderate-to-severe depression who have not improved on standard antidepressants, adding fresh weight to the idea a

A Cell study from the Francis Crick Institute links sensory nerve signaling to weaker anti-tumor immunity in lung cancer, pointing to a potential new way to strengthen immunotherapy.

A small clinical study suggests engineered immune cells may help some people with HIV maintain undetectable virus levels without ongoing medication, raising the prospect of longer-lasting control beyond daily antiretroir

Researchers at Memorial Sloan Kettering say antibodies found in acute myeloid leukemia patients who achieved long-term remission after bone marrow transplant helped reveal a new CAR T cell target that appears on leukemia

A Rutgers study points to senescent CD8+ T cells as a key reason some CAR T treatments fail, suggesting that the quality of the starting immune cells may shape whether the therapy can expand, persist, and work.

Researchers report a way to use engineered red blood cells to ferry mRNA into the body and reprogram myeloid immune cells to attack tumors, pointing to a potential alternative to conventional CAR cell manufacturing.

Researchers studying exceptional responders to glioblastoma therapy identified a molecule called miR-181d that appears to both weaken tumors and help the immune system remember and attack them.

Researchers report that gut “microbial fingerprints” can predict melanoma recurrence after surgery and immunotherapy with accuracy of up to 94%, pointing to a potential new biomarker for post-treatment risk assessment.

A Nature Medicine review traces the rapid advance of personalized mRNA cancer vaccines from experimental concept to active clinical development, marking a turning point for cancer immunotherapy.

New real-world data shows biologic therapies dramatically reduce severe asthma exacerbations in children, with the strongest benefits seen when treatment begins earlier in life.

Researchers are pairing lab-grown insulin cells with engineered immune bodyguards that prevent rejection — potentially eliminating the need for lifelong immunosuppression.

An 'off-the-shelf' neoantigen vaccine has demonstrated safety and immunogenicity in individuals with Lynch syndrome, a hereditary condition that dramatically increases cancer risk. The results advance the prospect of preventive cancer vaccines for people with genetic predispositions.